Clinical Trial Update: Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety trial comparing the biosimilar Reveliza with Actilise in ST-segment elevation myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• St-segment Elevation Myocardial Infarction

Drugs mentioned

• Actilise
• Reveliza

Snippet

Sponsor: AO GENERIUM | Conditions: Myocardial Infarction (MI) | Phase 3 | Status: COMPLETED